Volunteer dies 9 days after taking trial dose of covaxin; India Biotech said - not because of vaccine | Bharat Biotech claims death of Volunteer involved in trial of Kovaxin - Vaccine lost its life » India News
Connect with us

India News

Volunteer dies 9 days after taking trial dose of covaxin; India Biotech said – not because of vaccine | Bharat Biotech claims death of Volunteer involved in trial of Kovaxin – Vaccine lost its life

Published

on

  • Hindi news
  • National
  • Volunteer Dies 9 Days After Taking Trial Dose Of Covaxin; India Biotech Said Not Because Of Vaccine

Fed up with Ads? Install Dainik Bhaskar app for news without ads

new Delhi5 days ago

  • Copy link

Deepak Maravi of Bhopal gave a trial dose of Kovaxin on 12 December. After this, he died on 21 December. -File photo.

India Biotech is not missing out on the controversy over Kovaxin. The news of the suspected death of a 47-year-old volunteer involved in a trial of Kovacsin in Bhopal has been revealed. Volunteer Deepak Maravi participated in the trial of Kovacsin on 12 December. He died on December 21, the 9th day after taking the vaccine dose.

On December 22, when the autopsy was done, the body was confirmed to be poisoned. When this news came to the media on Friday, there was a stir. Bharat Biotech has given a clarification on Saturday on the question of the vaccine. The company said that the volunteer was given all the information about all the terms and conditions of the vaccine trial. He was also treated for the next 7 days after giving the vaccine.

What else did the company explain?

  • At the time of enrollment, Volunteer had met all the Phase-3 trial standards.
  • Volunteer was continuously monitored for 7 days after the dose was given. In this he was found perfectly healthy.
  • No side effects were observed on Volunteer.
  • According to the post mortem report of Gandhi Medical College, Bhopal, the cause of death may be cardiorespiratory failure. This may have happened due to poison in the body.
Deepak Maravi (file photo)

Deepak Maravi (file photo)

Controversy since approval of emergency use
Kovaxin is co-produced by Bharat Biotech and ICMR. It has also been approved for emergency use in the country. Since then, a dispute started over it. The Congress accused the government of hastily approving Kovaxin. It was said that the company has not yet completed the third phase trial. In such a situation, its use is not free from danger. The government had said that it has been approved only on the basis of the report of the trial. It has complied with all the standards. On Thursday 7 January, Bharat Biotech reported the completion of the third phase trial. 26 thousand people have participated in it.

Vomiting started with restlessness
Akash Maravi, the son of the deceased Deepak, told Dainik Bhaskar that his father’s health deteriorated on 19 December after the vaccine was given on 12 December. He suddenly started having vomiting with nervousness, restlessness, nausea. However, they did not treat it as a normal disease.

According to Deepak, the father had stopped going to labor since the dosas were performed, following the Corona protocol. When he died on December 21, he was alone at home. The mother had gone out of work and the younger brother was playing outside. The death notice was sent to the People’s College the same day. The next day, he was cremated at Subhash Nagar Vishram Ghat.

Advertisement

bareilly